In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ...

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...

Overall survival analysis showed median survival duration of 53.9 months (95% CI, 23.4 to not estimable) in the nivolumab arm ...

The data shows the prognostic value of Foresight CLARITY MRD detection at the end of frontline DLBCL in one of its largest prospective, real-world studies to date Data will be presented as an oral ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual ...

Q1 2025 Management View CEO Christopher Hall reported Q1 2025 revenue of $20.6 million, marking a strong start to the year. He highlighted significant progress in their "Win-in-MRD" strategy, driven ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will ...

CEO Chad Robins highlighted a strong start to the year, with MRD revenue increasing 34% year-over-year, driven by clinical volumes, ASP improvements, and pharma sequencing. The company received its ...

We know if we test for minimal residual disease [MRD] using a circulating-tumor DNA test called PhasED-Seq [phased variant enrichment and detection sequencing], that if that test is positive ...

Die Allianz hat im ersten Quartal einen Rekordgewinn erzielt. Dafür sorgten höhere Erträge aus dem Versicherungsgeschäft und ...

Guardant Health exceeds Q1 expectations, boosts growth outlook, and gains from favorable pricing and approvals. Read more about GH stock here.